COMMUNIQUÉS West-GlobeNewswire

Annual General Meeting of Kuros Biosciences approves all resolutions
15/04/2026
Annual General Meeting of Kuros Biosciences approves all resolutions Schlieren (Zurich), Switzerland, April 15, 2026 – Kuros Biosciences (“Kuros” or the “Company”) a leader in next generation bone healing technologies, [...]
PDS Biotech Announces Publication of Positive PDS01ADC Interim Phase 2 Clinical Trial Data from Stage 1 of NCI-led Metastatic Colorectal Cancer (mCRC) Trial
15/04/2026
78% Objective Response Rate (ORR) with PDS01ADC; Parallel trial without PDS01ADC had 35% ORR 2-year survival rate of >80%; Parallel trial without PDS01ADC resulted in 2-year survival rate of ~35% Trials performed in [...]
Alira Health and Autoimmune Neurology Alliance (AiNA) Launch AXIS Registry, Advancing Real-World and Patient-Centered Research in Autoimmune Neurology
15/04/2026
New registry connects patients and researchers to accelerate understanding and improve care in autoimmune neurological diseases FRAMINGHAM, Mass., April 15, 2026 (GLOBE NEWSWIRE) -- Alira Health, in partnership with the [...]
Callio Therapeutics to Present Poster on CLIO-8221, a Novel Dual-Payload Antibody-Drug Conjugate, at AACR 2026
15/04/2026
Callio Therapeutics is developing novel dual-payload antibody-drug conjugates (ADCs) designed to address resistance to existing cancer therapies, using proprietary linker and ADC platform technologies CLIO-8221 is a [...]
Inteleos Foundation Announces 2026 MedMissions Award to Advance Maternal Health Ultrasound Access in Five Nations
15/04/2026
ROCKVILLE, Md., April 15, 2026 (GLOBE NEWSWIRE) -- The Inteleos Foundation today announced five recipients of its 2026 MedMissions Award, supporting maternal health ultrasound access in Malawi, Sierra Leone, Kenya, [...]
Reviva Announces Letter to Shareholders
15/04/2026
CUPERTINO, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva,” the “Company” “we” or “us”), a late-stage pharmaceutical company developing therapies that seek to [...]
Filana Therapeutics Announces Publication in Epilepsia of Preclinical Simufilam Data
15/04/2026
Study in a well-accepted mouse model of severe Tuberous Sclerosis Complex (TSC) showed that simufilam attenuated the progression of seizures in a dose-dependent manner Results confirm and extend previously published [...]
Traws Pharma Announces Up to $60 Million Private Placement Financing
15/04/2026
Financing led by Sirenia Capital Management LP advances Traws Pharma's influenza program through a human challenge trial for tivoxavir marboxil in the United Kingdom NEWTOWN, Pa., April 15, 2026 (GLOBE NEWSWIRE) -- [...]
Polaryx Therapeutics Recognized with Pinnacle Award for Excellence in Pediatric Care
15/04/2026
Company selected as a Diamond honoree for Excellence in Pediatric Care PARAMUS, NJ, April 15, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics (Nasdaq: PLYX), a clinical-stage biotechnology company focused on developing [...]
Tango Therapeutics Announces Leadership Appointments to Accelerate Late-Stage Development of Vopimetostat
15/04/2026
- Matthew Gall appointed Chief Financial Officer - - Additional key appointments add expertise in clinical operations, corporate strategy and project leadership - BOSTON, April 15, 2026 (GLOBE NEWSWIRE) -- Tango [...]
Allogene Therapeutics Announces Nature Communications Publication Highlighting Pre-Clinical Data for ALLO-329, a Next Generation Dual-Targeted CD19/CD70 Allogeneic CAR T for Autoimmune Diseases
15/04/2026
Study Highlights Dagger ® Technology Showing that an Optimized CD70 CAR has the Potential to Protect Against Immune Rejection, Enabling Robust Expansion and Persistence of Allogeneic CAR T Cells in Pre-Clinical Models [...]
Nexalin Advances FDA Alzheimer’s Strategy Following Landmark Leadership Meetings in the U.S. and China
15/04/2026
Company Designing FDA Application Amendments and U.S. Clinical Strategy Leveraging Extensive Real-World Neurostimulation Data Sets Reflecting Broad Clinical Experiences HOUSTON, TX, April 15, 2026 (GLOBE NEWSWIRE) -- [...]
Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026
15/04/2026
DUBLIN and BRIDGEWATER, N.J., April 15, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company advancing the science of cardiovascular therapeutics worldwide, today announced that it will report first [...]
Scienture Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement
15/04/2026
COMMACK, NY, April 15, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (“Scienture”) a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to [...]
neffy® approved as the first needle-free anaphylaxis treatment of adults and children in Canada
15/04/2026
ALK (ALKB:DC / Nasdaq Copenhagen: ALK B) today announced that Health Canada has approved neffy ® 2 mg for the emergency treatment of allergic reactions (anaphylaxis) due to insect stings or bites, foods, medicinal [...]
Orvida Pharma (formerly Kamari Pharma) Announces Favorable Phase 1a Safety Data for KM-023, a Potential First-in-Disease Oral TRPV3 Inhibitor, and Initiation of Phase 1b Study in Patients with Olmsted Syndrome
15/04/2026
First Olmsted syndrome patient dosed in global Phase 1b study Company now operating under its new name, Orvida Pharma NESS ZIONA, Israel, April 15, 2026 (GLOBE NEWSWIRE) -- Orvida Pharma (formerly Kamari Pharma), a [...]
Cannabis Industry Pioneers Launch grnroom, a Creative Marketing Agency
15/04/2026
VANCOUVER, British Columbia and TORONTO, April 15, 2026 (GLOBE NEWSWIRE) -- After more than a decade building brands, media platforms, and cultural moments within the cannabis industry, a group of experienced operators [...]
neffy® (epinephrine nasal spray) Approved in Canada as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)
15/04/2026
neffy offers a new delivery method for epinephrine in Canada for adults and children ( > 30 kg) living with severe allergic reactions ALK- Abelló A/S, which licenses the rights to market neffy in Canada, expects [...]
BioCryst to Report First Quarter 2026 Financial Results on May 6
15/04/2026
RESEARCH TRIANGLE PARK, N.C. , April 15, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its first quarter 2026 financial results on Wednesday, May 6, [...]

Pages